Immunological role and prognostic value of the SKA family in pan-cancer analysis

Zhengtian Li, Lanying Huang, Jiachen Li, Wenkang Yang, Weichao Li, Qiuzhong Long, Xinyu Dai, Hongtao Wang, Gang DuFrontiers in Immunology 2023 · DOI

TL;DR

Researchers have developed a novel "SKA score" to quantify the activity of the spindle and kinetochore-associated (SKA) gene family across 33 different cancer types. The study reveals that a high SKA score is a powerful biomarker for poor prognosis and an immunosuppressive tumor environment, yet paradoxically predicts a significantly better response to anti-PD-1/L1 immunotherapies.

What Problem Does This Paper Address?

During mitosis, the cell must ensure that chromosomes are partitioned equally. The SKA complex (comprising SKA1, SKA2, and SKA3) is essential for this, stabilizing the connection between the kinetochore and the spindle microtubules. While individual SKA genes have been linked to progression in specific cancers like liver or breast cancer, a "pan-cancer" perspective was missing.

The authors sought to address whether the SKA family functions as a universal oncogenic driver. Specifically, they investigated how these mitotic regulators influence the Tumor Microenvironment (TME)—the complex ecosystem of immune cells and signaling molecules surrounding a tumor—and whether they can predict how a patient will respond to modern immunotherapy.

Methods

The researchers employed a multi-omics bioinformatic approach combined with laboratory validation:

  • The SKA Score: The core innovation is a scoring system developed using single-sample gene set enrichment analysis (ssGSEA). This allowed the authors to transform the expression levels of the three SKA genes into a single, quantifiable metric for each patient sample.
  • Computational Pipelines: They used GSVA (Gene Set Variation Analysis) to identify biological pathways linked to the score and ESTIMATE/TIMER2 algorithms to map immune cell infiltration.
  • Drug Sensitivity Analysis: The team cross-referenced SKA expression with the CTRP and GDSC databases to identify potential small-molecule inhibitors.
  • Experimental Validation: To move beyond "dry lab" data, they performed Immunohistochemistry (IHC) on clinical samples of breast and gastric cancer to confirm that SKA protein levels were indeed higher in tumors compared to healthy tissue.

Datasets

The study integrated data from several massive public repositories:

  • TCGA (The Cancer Genome Atlas): Primary source for transcriptomic and clinical data across 33 cancer types.
  • GTEx (Genotype-Tissue Expression): Used for "normal" tissue baseline comparisons.
  • GEO (Gene Expression Omnibus): Specifically the GSE91061 cohort for melanoma.
  • IMvigor210: A specialized dataset for bladder cancer patients treated with anti-PD-L1 therapy.
  • STRING Database: Used for protein-protein interaction mapping.

Key Insights and Ideas

  • The Mitosis-Immune Connection: One of the most striking findings is that high SKA activity—traditionally viewed purely as a cell-cycle mechanism—is strongly correlated with an immunosuppressive TME. High-score tumors showed lower infiltration of antitumor cells like CD8+ T cells and Natural Killer (NK) cells.
  • The Immunotherapy Paradox: Usually, markers of "aggressive" cancer imply a harder-to-treat disease. However, patients with high SKA scores actually showed superior responses to immunotherapy (anti-PD-1/L1). This suggests that the genomic instability or high proliferation signaled by the SKA score might make tumors more "visible" to the immune system once checkpoint inhibitors are applied.
  • Epigenetic Silencing: The study confirmed that DNA methylation acts as a "brake" on SKA genes. In many cancers, this methylation is lost, effectively "jamming the accelerator" on cell division.
  • Universal Risk Factor: The SKA score was identified as a significant risk factor for overall survival in 11 cancer types, including Kidney Renal Papillary Cell Carcinoma (KIRP) and Brain Lower Grade Glioma (LGG).

Key Results

  • Prognostic Power: High SKA scores were associated with significantly shorter survival times across the majority of the 33 cancer types studied.
  • Pathway Enrichment: The SKA score was positively linked to E2F targets, G2M checkpoints, and DNA repair pathways, confirming its role in driving rapid, albeit potentially error-prone, cell division.
  • Immunotherapy Outcomes: In the IMvigor210 (bladder cancer) cohort, patients with high SKA scores had a significantly higher Objective Response Rate (ORR) and longer survival compared to those with low scores.
  • Therapeutic Targets: The analysis identified several small molecules, such as trametinib and selumetinib, whose efficacy may be influenced by SKA family expression, suggesting potential combination therapy strategies.

Limitations and Future Work

While the study provides a robust framework, the authors acknowledge several hurdles:

  • Retrospective Nature: The findings are based largely on existing databases. Prospective clinical trials are necessary to validate the SKA score as a tool for bedside decision-making.
  • Mechanistic Gaps: While the correlation between SKA activity and immune suppression is clear, the exact molecular "crosstalk" (how a mitotic protein signals to an immune cell) remains to be fully elucidated through in vitro and in vivo functional studies.
  • Data Imbalance: Some rare cancer types had smaller sample sizes in the TCGA, which may affect the statistical power of the findings for those specific diseases.

Summary updated

Abstract

The SKA score plays a critical role in 33 cancer types and is highly related to tumor prognosis. Patients with elevated SKA scores have a clear immunosuppressive TME. The SKA score may serve as a predictor for patients receiving anti-PD-1/L1 therapy.
BibTeX
@inproceedings{li2023immunological,
  author = {Zhengtian Li and Lanying Huang and Jiachen Li and Wenkang Yang and Weichao Li and Qiuzhong Long and Xinyu Dai and Hongtao Wang and Gang Du},
  title = {{Immunological role and prognostic value of the SKA family in pan-cancer analysis}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1012999},
}
Figure